TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05090436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Exercise
Description: two month (three session per week)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (physiotherapy techniques)
Description: two month (three session per week)
Study: NCT05691127

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count (CBC), C reactive protein (CRP(., Chest x ray, ABG, Electrolytes, Random blood sugar, Creatinine
Description: I will use these investigations in my study
Study: NCT06485102

Intervention type: PROCEDURE
Intervention: Carotid Surgery in patients with symptomatic or asymptomatic stenosis
Description: Carotid Surgery in patients with symptomatic or asymptomatic stenosis
Study: NCT06542744

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: The subjects will follow usual care instructions. Subjects are not trained in the use of Emagina.
Study: NCT06070168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Mothers in labor after normal birth at the postpartum clinic At least 6 hours later and for cesarean births, the researcher will visit the patient after 12 hours.~Mothers will be interviewed according to the inclusion criteria and exclusion criteria, and will be informed about the study.~will be given and their consent will be taken, the mother information form and the Edinburgh Postpartum Depression Scale (EPDS) form will be filled in, a pre-test will be done and the communication will be completed.~will get their numbers. The researcher will contact the experimental group by phone. He will introduce himself and 6 weeks (during postpartum) It will provide the mother with the consultancy service she needs about herself and the newborn 24 hours a day. After 6 weeks, the training will end and the third researcher will make post-tests of the depression scale to both groups without knowing the experimental and control groups.
Study: NCT06108674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care via telepharmacy and usual care
Description: Pharmacotherapeutic monitoring via telephone consultation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical care in-person and usual care
Description: Face-to-face pharmacotherapeutic monitoring
Study: NCT05891873

Intervention type: DIAGNOSTIC_TEST
Intervention: CAM-ICU
Description: Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.

Intervention type: DIAGNOSTIC_TEST
Intervention: ICDSC
Description: Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.

Intervention type: DIAGNOSTIC_TEST
Intervention: 4AT
Description: Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.

Intervention type: DIAGNOSTIC_TEST
Intervention: p(s)CAM-ICU
Description: Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.

Intervention type: DIAGNOSTIC_TEST
Intervention: CAPD
Description: Patients who meet the inclusion criteria will be screened daily for delirium using the screening test mentioned above.

Intervention type: DIAGNOSTIC_TEST
Intervention: MASTcz (The Mississippi Aphasia Screening Test)
Description: People with aphasia will be examined by a skilled speech therapist.

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG
Description: Patients with positive delirium will undergo EEG examination. 10-min native EEG.

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG
Description: Patients with positive delirium will undergo EEG examination. 10-min native EEG.
Study: NCT06017011

Intervention type: OTHER
Intervention: Total contact cast
Description: Total contact cast will be put on the patient at the diagnosis of Acute charcot neuroarthropathy and the patient will be followed till clinical remission and after that till 6months post clinical remission. F18 Fluoride PET scan and MRI of the foot with DWI and ADC sequence to be done at baseline, Clinical remission, 3months post clinical remission and 6months post clinical remission to quantitate the process of remission.
Study: NCT05885529

Intervention type: OTHER
Intervention: UCH-L1 GFAP
Description: measurment of UCH-L1 GFAP within 12 hours in adult patients after a mild traumatic brain injury
Study: NCT06005337

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Blogshots 1-3
Description: 1. Don't routinely do a throat swab when children present with a sore throat if they have a cough, rhinitis, or hoarseness~2. Don't recommend the use of cough and cold remedies in children under six years of age~3. Don't use antibiotics for acute asthma exacerbations without clear signs of bacterial infection

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Blogshots 4-6
Description: 1. Don't routinely use antibiotics in children with uncomplicated sore throats~2. Don't prescribe antibiotics in adults with bronchitis/asthma and children with bronchiolitis~3. Don't use antibiotics in adults and children with uncomplicated acute otitis media
Study: NCT05775263

Intervention type: PROCEDURE
Intervention: CT angiogram
Description: CT angiography of the brain 30 minutes from establishment of NRP

Intervention type: PROCEDURE
Intervention: CT angiogram
Description: CT angiography of the brain 30 minutes from establishment of NRP
Study: NCT05266976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 Weeks of Supervised Resistance Exercise Training
Description: Participants will be randomized to complete 10 weeks of either resistance (weight lifting, hopping) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 Weeks of Supervised Endurance Exercise Training
Description: Participants will be randomized to complete 10 weeks of endurance (stationary cycling) supervised exercise. Exercise will be 3x per week for 1 hour each session. There are a total of 30 exercise sessions.
Study: NCT05539599

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive evaluation
Description: Non-ultrasound parameters: Central venous pressure, hand-grip strength evaluation, P0.1, Maximal inspiratory pressure, Blood gas analysis ultrasound parameters: Diaphragmatic displacement, thickening fraction, TFmax, E/e', Triscuspidal annular Plane Systolic Excursion, Lung score
Study: NCT03912350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balovaptan
Description: Participants will receive 1 tablet of balovaptan once daily (QD) on Days 1 through 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: Participants will receive 1 tablet of balovaptan once daily (QD) on Days 1 through 14.
Study: NCT05567601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOXIL/CAELYX
Description: 40 mg/m2 as a 90-minute IV infusion via a central venous catheter or peripheral vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL/CAELYX
Description: 40 mg/m2 as a 90-minute IV infusion via a central venous catheter or peripheral vein
Study: NCT05585268

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication reconciliation supplemented with MedSafer and deprescribing brochures
Description: This unit will act as an intervention unit for the MedRec where MedSafer deprescribing reports will be handed to the treating team and deprescribing brochures from the Canadian Deprescribing Network will be given to patients.
Study: NCT05103085

Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid diagnostic orientation test (TROD) for Hepatitis C
Description: Inclusion of patients during the consultation with the gastroenterologist, before hospitalization in the digestive endoscopy department. Each consenting patient benefits from a HCV screening using TROD on the day of their hospitalization in the department.
Study: NCT05854316

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Comprehensive Biomechanical assessment
Description: Magnetic resonance images, electromyography and dynamometry data will be used, together with data from the gait assessment and clinical questionnaires/measures, to characterize the biomechanics of the participants, and to develop and inform personalised musculoskeletal models
Study: NCT02920762

Intervention type: OTHER
Intervention: on-interventional study - retrospective database review

Intervention type: OTHER
Intervention: on-interventional study - retrospective database review

Intervention type: OTHER
Intervention: on-interventional study - retrospective database review

Intervention type: OTHER
Intervention: on-interventional study - retrospective database review

Intervention type: OTHER
Intervention: on-interventional study - retrospective database review

Intervention type: OTHER
Intervention: on-interventional study - retrospective database review

Intervention type: OTHER
Intervention: on-interventional study - retrospective database review

Intervention type: OTHER
Intervention: on-interventional study - retrospective database review
Study: NCT05179889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Irinotecan 150 mg/m2 IV day 1, oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 48 hours) continuous infusion\] 12 cycles per 2 weeks~mFOLFOX 6 \[Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX 6
Description: Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 weeks
Study: NCT05420701

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEE
Description: Patients in the surgical arm (LAAC) will be arranged to do TEE, which is not considered standard of care.
Study: NCT05457686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: According to this, the proximal part of the band is located close to the lymph node. In our study, as stated in the literature, the proximal part of the tape will be adhered to the fibular head area next to the lymph nodes without applying any stretching. Then 5-10% stretching is applied and the distal part is adhered. 2 separate tapes are applied so that the strips cross each other

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham taping
Description: In the same procedure and time as kinesiotaping, inelastic tape will be used instead of kinesiotape.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Routine exercise and physiotherapy program applied after knee arthroplasty surgery will be applied

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Routine exercise and physiotherapy program applied after knee arthroplasty surgery will be applied

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Routine exercise and physiotherapy program applied after knee arthroplasty surgery will be applied
Study: NCT05147545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity physical effort
Description: Pedaling 15 minutes at 75 Watt then 100 Watt of the ergometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity physical effort
Description: Pedaling 3 minutes at the 30 Watt level of the ergometer
Study: NCT05643937

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine health education
Description: The control group received routine health education after catheterization, including introducing the purpose, method, advantages and complications of PICC insertion to patients before catheterization and signing informed consent. During catheterization, PICC assistant explained relevant matters needing attention and cooperative actions to the patient. After catheterization, patients were instructed to carry out grip training and limb activities.
Study: NCT05147545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperlipidic meal
Description: Eating an hyperlipidic meal 60 minutes after a physical effort

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperlipidic meal
Description: Eating an hyperlipidic meal 60 minutes after a physical effort
Study: NCT05643937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine health education + precise health education
Description: On the basis of routine health education in the control group, the experimental group screened the high-risk behaviors of patients through the questionnaire of daily life behavior habits, and formulated the precise and concrete health education program for their high-risk behaviors
Study: NCT04133701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding
Description: After baseline measurements have been completed, participants will enroll in a time-restricted feeding intervention. Participants will be asked to restrict the time in which they eat each day to 10 hours, fasting for the remaining 14 hours. Participants will also be asked to finish their last meal of the day at least 2 hours prior to bedtime.
Study: NCT05666037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile health intervention(mHealth)
Description: The intervention group will receive mobile health messaging intervention on behavior change to uptake early postpartum modern contraceptive method.
Study: NCT05147545

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measure of circulating DNA
Description: Multiple measure of circulating DNA: on an empty stomach, at the end of the physical effort, after 15, 30 and 60 minutes of rest, 120 minutes after an hyperlipidic meal.~An additional measure will occur for subjects free of malignancy during the effort.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measure of circulating DNA
Description: Multiple measure of circulating DNA: on an empty stomach, at the end of the physical effort, after 15, 30 and 60 minutes of rest, 120 minutes after an hyperlipidic meal.~An additional measure will occur for subjects free of malignancy during the effort.
Study: NCT05727280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercise Practices
Description: The intervention planned within the scope of the research are the Progressive Relaxation Exercise application. Patients in the intervention group undergoing open heart surgery will be given training on progressive relaxation exercise in the patient's room the day before the surgery. Correct breathing techniques will be taught and the relaxation exercises will be performed by using audio recordings. Afterwards, the relaxation exercise will be provided to the patient to practice the progressive relaxation exercise with mp3 accompaniment. After open heart surgery, progressive relaxation exercise will be applied to the patient on the 1st, 2nd and 3rd days of his admission to the service. The patient will be asked to perform the progressive relaxation exercise twice a day, once during the day and once in the evening.
Study: NCT05241899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib + RC48
Description: Fruquintinib (4mg orally, once daily for 3 wks on/1 wk off) combined with of RC48( 2.5mg/kg by intravenous infusion during 30-90 min every 2 weeks)
Study: NCT05203419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHS552
Description: MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHS552
Description: MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHS552
Description: MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHS552
Description: MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
Study: NCT06330077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifenprodil
Description: Treatment administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment administration
Study: NCT06177509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Aerobic Exercise
Description: Participants will follow a sub-symptom aerobic exercise program (approx. 30 min) 3 - 5 times pr week for twelve weeks. Sub-symptom threshold aerobic exercise means to exercise at 80-90% of the maximum threshold heart rate achieved during the BCTT. To ensure proper exercise dose and progression, participants will be retested every three weeks. During the first three weeks, the participants will be offered one weekly guided exercise session. The other 2 - 4 weekly sessions the participants will carry out on their own, choosing activities based on experience, preferences and possibilities (e.g. walking, jogging, stationary bike, swimming). The intensity of the sub-symptom threshold aerobic exercise will be monitored using a heart rate monitor and the BORG scale. Compliance with the sub-symptom threshold aerobic exercise program will be recorded by the patients in an exercise diary, which is followed up by a weekly reminder over the phone/sms by a physiotherapist in the project.
Study: NCT06013761

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm
Description: 12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared with 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8) in a within-subject-crossover design in 28 patients with drug-resistant epilepsy. In order to enable the highest possible adherence, there are no restrictions on the composition of the food.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IF 16:8 as active comparator vs. IF MCT 16:8 as experimental arm
Description: 12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared with 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8) in a within-subject-crossover design in 28 patients with drug-resistant epilepsy. In order to enable the highest possible adherence, there are no restrictions on the composition of the food.
Study: NCT04427540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin 10 micrograms IM
Study: NCT04820764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMech MVRS
Description: CardioMech MVRS
Study: NCT04239989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib Adipate
Description: Given PO
Study: NCT04773587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Cream 0.15%
Description: Roflumilast Cream 0.15% - Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Cream - Vehicle
Study: NCT05509972

Intervention type: DEVICE
Intervention: total knee prosthesis implantation
Description: Total Knee Arthroplasty (TKA) represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or comparable conditions even in young patients compromised by knee pain and limitations of daily living

Intervention type: DEVICE
Intervention: total knee prosthesis implantation
Description: Total Knee Arthroplasty (TKA) represents a well-established, reliable and successful treatment option for end-stage bicompartmental osteoarthritis or comparable conditions even in young patients compromised by knee pain and limitations of daily living
Study: NCT04632628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Cognitive Behavior Therapy for Insomnia (CBT-I)
Description: Participants will complete 4 web-based CBT- I sessions. Lesson 1: Sleep Hygiene and Stimulus Control Lesson 2: Sleep Restriction and Relaxation Strategies Lesson 3: Identifying and Restructuring Dysfunction Thoughts Lesson 4: Practical Recommendations, Review, and Maintenance of Change
Study: NCT04559217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical 68Ga-DOTATATE
Description: Injection of 68Ga-DOTATATE followed by PET/CT acquisition
Study: NCT06346054

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Breath analysis
Description: Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breath analysis
Description: Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Breath analysis
Description: Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood analysis
Description: Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood analysis
Description: Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood analysis
Description: Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood
Study: NCT06421623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program Including Various Workshops aiming to preserve elderly's autonomy through foot health
Description: Combination of minimalist footwear, foot massages, and workshops to re-learn walking and posture
Study: NCT06394921

Intervention type: PROCEDURE
Intervention: 2 day cardiopulmonary exercise test
Description: Consecutive day 2 day CPET and follow up for 7 days for subjective feelings/fatigue.
Study: NCT05743686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application
Description: The participants will have access to an app allowing them to report their adverse effects to oral chemotherapy. Basic advices will be given and the hospital pharmacists will be warned.